NasdaqGS:AMGNBiotechs
A Look At Amgen (AMGN) Valuation After Q1 Beat Guidance Upgrade And US$300 Million US Expansion
Amgen (AMGN) is back in focus after first quarter results showed higher revenue and net income versus a year earlier, along with fresh full year guidance and a new US$300 million US manufacturing investment.
See our latest analysis for Amgen.
The stock has given investors a 32.3% total shareholder return over the past year, even as the 90 day share price return is down 8.1%. This suggests that earlier momentum has cooled while the latest earnings, guidance and US$300 million manufacturing...